mProX™ Human NCR1 Stable Cell Line

Product Information

Target Family

Other Targets

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;YT

Target Classification

Other Targets Drug Discovery Assays and Products

Target Research Area

Cancer Research

Related Diseases

Hydatidiform Mole, Recurrent, 1; Gestational Trophoblastic Neoplasm

Gene ID

Human:9437

UniProt ID

Human:O76036

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

NCR1, also known as NKp46, is a biomarker that plays a role in various immune processes. In a study on vitiligo, the JAK3/TEC family kinase inhibitor ritlecitinib downregulated immune biomarkers and upregulated melanocyte-related markers in the skin and blood of participants, suggesting its potential in treatment. Another study found that STAT4, which is regulated by NCR1, has divergent roles in shaping the differentiation of cytotoxic ILC1 and NK cells during gut inflammation. Methionine enkephalin inhibited cervical cancer migration and activated CD11b(+) NCR1(+) NK cells in the tumor microenvironment. IL-25 was found to regulate metabolism and other biological processes in NK cells, providing insight into its role and regulatory mechanisms. In soft tissue sarcoma, intratumoral NKp46(+) NK cells were associated with improved overall survival and were spatially distanced from T cells and MHC-I(+) cells. These findings have implications for prognosis and immunotherapy treatment selection.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human NCR1 Stable Cell Line (S01YF-1023-PY280). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Jordan Johnson (Verified Customer)

What is the role of NCR1 in sterol translocation? May 31 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

NCR1 drives sterol translocation across vacuoles in yeast by undergoing conformational changes, suggesting its importance in sterol homeostasis. May 31 2020

chat Jordan Brown (Verified Customer)

How does NCR1 contribute to immune responses? Jan 03 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

NCR1, expressed on natural killer cells, plays a role in controlling systemic infections like vaccinia virus through IFN-γ gene function, indicating its importance in immune surveillance. Jan 03 2022

Published Data

Fig.1 Approximately half as many ZIKV-infected JEG-3 cells were terminated by NCR1 KO YT cells in comparison to YT cells that had been transfected with nontargeting sgRNAs, as observed in the experiment.

The targeting of 722.221 cells, uninfected or ZIKV-infected JEG-3 cells by human NK cell line YT cells was performed using YT cells that had been subjected to knockout procedures for NCR1 or NCR3, or were exposed to control single-guide RNAs (n = 3-6 samples), resulting in specific killing.

Ref: Sen Santara, Sumit, et al. "The NK cell receptor NKp46 recognizes ecto-calreticulin on ER-stressed cells." Nature 616.7956 (2023): 348-356.

Pubmed: 37020026

DOI: 10.1038/s41586-023-05912-0

Research Highlights

Guttman-Yassky, Emma. et al. "Improvements in Immune/Melanocyte Biomarkers With JAK3/TEC Family Kinase Inhibitor Ritlecitinib in Vitiligo." The Journal of allergy and clinical immunology, 2023.
In this research, the focus was on Vitiligo, an autoimmune depigmenting condition with limited treatment options. The study, conducted as part of a phase 2b trial, investigated the impact of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, on skin and blood biomarkers in individuals with nonsegmental vitiligo. Over 65 adults with this condition received different doses of ritlecitinib over 24 weeks. The results demonstrated a reduction in immune biomarkers and an increase in melanocyte-related markers with ritlecitinib treatment, especially in the 50 mg group. These findings suggest the potential of ritlecitinib in vitiligo treatment, supported by a positive correlation with clinical response.
Guttman-Yassky, Emma. et al. "Improvements in Immune/Melanocyte Biomarkers With JAK3/TEC Family Kinase Inhibitor Ritlecitinib in Vitiligo." The Journal of allergy and clinical immunology, 2023.
Pubmed: 37777018 DOI: 10.1016/j.jaci.2023.09.021

Scarno, Gianluca. et al. "Divergent roles for STAT4 in shaping differentiation of cytotoxic ILC1 and NK cells during gut inflammation." Proceedings of the National Academy of Sciences of the United States of America, 2023.
The effector responses of natural killer (NK) cells and type 1 innate lymphoid cells (ILC1) are dependent on the signal transducer and activator of transcription 4 (STAT4), which also plays a crucial role in protection against pathogens. Through the use of genetic and transcriptomic analyses, the authors have identified distinct functions of STAT4 in regulating effector differentiation of these closely related cell types. These findings shed light on the divergent roles of STAT4 in the immune response.
Scarno, Gianluca. et al. "Divergent roles for STAT4 in shaping differentiation of cytotoxic ILC1 and NK cells during gut inflammation." Proceedings of the National Academy of Sciences of the United States of America, 2023.
Pubmed: 37756335 DOI: 10.1073/pnas.2306761120